LAVA Therapeutics NV — Investor Presentation (February 2023)
46 slides from LAVA Therapeutics NV's investor presentation, Feb 16, 2023
Slide 1: Gamma delta T cell engagers for next-generation cancer therapeutics
Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation February 2023
Slide 2: Legal Disclosure: Forward-looking Statements
Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expe
Slide 3: Pioneering Next-Generation Cancer Therapeutics
Pioneering Next-Generation Cancer Therapeutics ©LAVA Therapeutics 2023 3 • Bispecific antibody platform to engage Vγ9Vδ2 T cells for highly specific tumor cell killing – Leverage the unique quality of Vγ9Vδ2 T cells to selectively kill tumor cells while sparing normal cells – Fully modular approach
Slide 4: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications
MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody™ Pipeline: Potential in Hematological and Solid Tumor Indications 4 Cand
Slide 5: Team Led by Experienced Leaders in the Biotech and Pharma Field
Ton Adang, PhD CDO • Vast experience in drug development • Extensive experience in product discovery and project management (e.g., KEYTRUDA) HansvanderVliet,MD,PhD CSO • Inventor of LAVA’s gamma delta T cell engager platform • Medical oncologist, extensive experience in pre-clinical and clinical res
Slide 6: LAVA's Proprietary Gammabody Platform
LAVA’s Proprietary Gammabody™ Platform Bispecific Gamma Delta T Cell Engagers 6
Slide 7: Enthusiasm for Bispecific T Cell Engagers
Enthusiasm for Bispecific T Cell Engagers ©LAVA Therapeutics 2023 7 • High expectations for T cell bi-specific therapies driving significant development • 200+ Bispecific Antibodies in the Clinic, 7 approved 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 20
Slide 8: Enthusiasm for Bispecific T Cell Engagers
• High expectations for targeted T cell therapies in cancer, but often: – Narrow therapeutic window: – Cytokine Release Syndrome – On-target/off-tumor-related toxicities – Activates immunosuppressive T cells – Sporadic efficacy in solid tumors therapeutic window therapeutic effect toxic effect ©LAVA
Slide 9: Strategies for Widening the Therapeutic Window
• Selecting ‘tumor-specific’ targets • Step-dosing / subcutaneous dosing • Decreasing affinity for T cells • Masking/site-specific activation • Recruiting alternative effector cells • Address only narrow target range, and/or • Cumbersome, and/or • Strongly decrease potency ©LAVA Therapeutics 2023 9
Slide 10: Gammabody Platform: Bispecific γδ T Cell Engagers
Gammabody™ Platform: Bispecific γδ T Cell Engagers DIFFERENTIAL APPROACH A versatile bispecific antibody platform for developing novel cancer therapeutics MECHANISM OF ACTION LAVA's proprietary bispecific antibodies are designed to: – Target Vγ9Vδ2 T cells to tumor antigens initiating selective tumo
Slide 11: Bispecific γδ T cell-engagers harness innate and adaptive immunity
Bispecific γδ T cell-engagers aim to harness innate & adaptive immunity • Largest γδ-T cell subset in blood: (~90-95% of total γδ-T cells) • Natural ability to recognize and kill tumor cells • Highly cytotoxic • Relatively abundant in tumor-infiltrating lymphocytes • Presence of γδ T cells associate
Slide 12: Off-the-Shelf Gammabody Platform Directs Vγ9Vδ2 T Cells to Cancer Cells
Off-the-Shelf Gammabody™ Platform: Enhances Innate Tumor Recognition by Directing Vγ9Vδ2 T Cells to the Cancer Cells LAVA’s Gammabody™ directs Vγ9Vδ2 T cells to tumors with high affinity to induce direct tumor cell killing and orchestrate an immunological cascade of anti-cancer responses and while r
Slide 13: Cascade of Anti-Cancer Responses
Cascade of Anti-Cancer Responses – Potential Translation to Favorable Therapeutic Window Efficacy: • Potent killing of cancer cells (EC50s in the low picomolar range) • No co-activation of immune-suppressive Tregs which dampen antitumor efficacy of cytotoxic T cells • Orchestrate innate and adaptive
Slide 14: Expansion and Cascade Response Without Treg Activation in Preclinical Models
Gammabody™ can induce robust gamma delta T cell expansion and can amplify the anti- tumor immune response via downstream activation of other immune cells while avoiding co-activation of immunosuppressive T cells such as Tregs Expansion Cascade Response No Treg Activation Gammabody™ - Mediated Expans
Slide 15: Gammabody Selectively Kills Cancer Cells While Sparing Healthy Cells
Gammabody™ Can Selectively Kill Cancer Cells While Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models • 2:1 ratio ( T cells : Target cells) • Similar CD20 expression levels on C1R neo and B-cells CD20 Gammabody™ Mediated Killing PSMA Gammabody™ Mediated Killing Preferential kil
Slide 16: Non-Clinical Safety Data Indicate Good Tolerability
Non-Clinical Safety Data Indicate Good Tolerability • Non-clinical safety studies using Gammabody™ molecules designed for cross-reactivity support the benign safety profile of the platform • NHP studies completed with Gammabody™ molecules targeting CD1d, CD20 and EGFR – CD1d, CD20 targeting surrogat
Slide 17: Gammabody Platform: A Novel T cell engager approach for cancer therapy
Gammabody™ Platform: A Novel T cell engager approach for cancer therapy γδ T cell engager platform • Highly potent (kills at picomolar concentrations) • Recruits additional immune effector cells by antigen presentation and cascade response • No activation of regulatory T-cells • Tumor-cell selective
Slide 18: Clinical-stage company
Clinical-stage company 18
Slide 19: LAVA-051 Targets CD1d for CLL, MM and AML
19 LAVA-051 Targets CD1d to Activate Vγ9Vδ2 T Cells and iNKT Cells for the Potential Treatment of CLL, MM & AML
Slide 20: LAVA-051: First-in-Class Gammabody Targeting CD1d
Format • Humanized bispecific single domain antibody (bsVHH) of 27kDa ‒ Short plasma half-life, prolonged functional half-life through high affinity TCR binding Mechanism of Action • Engages Vγ9Vδ2 T cells to mediate potent killing of CD1d-expressing tumor cells – Activates iNKT cells to mediate kil
Slide 21: LAVA-051: Pre-Clinical Data Support Mechanism of Action and Function
LAVA-051: Pre-Clinical Data Support Mechanism of Action and Function 21 Expansion of Vγ9Vδ2 T and iNKT cells Lysis of patient tumor cells Adapted from Lameris et al., submitted Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 0 20 40 60 80 100 CLL specific lysis (relative %) 0 20 40 60 80
Slide 22: LAVA-051 Phase 1/2a in Hematological Malignancies
LAVA-051 Phase 1/2a in Hematological Malignancies • Primary objectives: investigate safety and tolerability of LAVA-051 and determine the recommended Phase 2 dose • Secondary objectives: include evaluation of PK, PD, immunogenicity and preliminary antitumor activity • LAVA-051 administered as 2-hour
Slide 23: LAVA-051 Initial Phase Data - Safety
LAVA-051 – Initial Phase 1 Data - Safety • LAVA-051 has reached a dose of 200 mg (~400x the starting dose) in MM and CLL patients • Most observed AEs have not been suspected to be related • Frequency and severity of AEs have not correlated with increasing dose levels • No CRS and no ICANS (ASTCT) an
Slide 24: LAVA-051 Initial Phase Data - Pharmacodynamics
24 LAVA-051 – Initial Phase 1 Data – Pharmacodynamics • Pharmacodynamic parameters reflect changes expected for the LAVA-051 mechanism of action – Vγ9Vδ2-T cell activation markers (CD25 and CD69) upregulated following dosing – Maximum Vγ9Vδ2 T cell receptor occupancy (RO) increased with dose ASCO 20
Slide 25: LAVA-051 Pharmacokinetics
25 LAVA-051 – Pharmacodynamics ASH 2022 abstract #2014 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 Pharmacokinetics 1st dose IV, 2nd dose SC patient 32-001 cohort #5 IV SC IV • Linear LAVA-051 pharmacokinetics • SC bioavailability 74% compared to IV (based on data from Pt 32-00
Slide 26: LAVA-051 Patient Characteristics and Time on Treatment
LAVA-051 – Initial Phase 1 Data - Patient Characteristics and Time on Treatment MM/CLL 6/6 Male/Female 8/4 Median age (range) 69 (59-76) Prior therapies, median (range) – MM/CLL 4 (3-5) / 5.5 (4-13) ASH 2022 abstract #2014, corrected Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 * Deat
Slide 27: LAVA-051 Potential Signs of Activity
LAVA-051 – Initial Phase 1 Data - Potential Signs of Activity CLL • Patient with R/R CLL (15 mg) • Temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ‒ Resembled a tumor-flare reaction, as reported in CLL with lenalidomide • Patient asses
Slide 28: LAVA-051: Summary of Initial Phase Data Presented
LAVA-051: Summary of Initial Phase 1 Data Presented • LAVA-051 is a next-generation bispecific γδ T cell engager designed for a broad therapeutic window • LAVA-051 has reached a dose of 200 mg (400x the starting dose) in MM and CLL patients – Most observed Adverse Events (AEs) have not been suspecte
Slide 29: LAVA-1207 Targeting PSMA for mCRPC
LAVA-1207 Gammabody™ that Activates Vγ9Vδ2 T Cells by Targeting PSMA for the Treatment of mCRPC
Slide 30: LAVA-1207: PSMA-targeting Gammabody for Prostate Cancer
LAVA-1207: PSMA-targeting Gammabody™ for Prostate Cancer Format • Contains a Fc domain for extended plasma half-life; silenced to avoid off-target T cell activation • Small size (compared to regular IgG antibodies) to facilitate tumor penetration Mechanism of Action • Specifically directs Vγ9Vδ2 T c
Slide 31: LAVA-1207: Preclinical Data in Patient Samples
LAVA-1207: Preclinical Data Support Activity and Selectivity in Patient Samples • LAVA-1207 triggers activation of autologous Vγ9Vδ2 T cells in the presence of patient-derived tumor cells • LAVA-1207 induces selective tumor cell lysis Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 31 Me
Slide 32: LAVA-1207 Phase 1/2a Study Design
LAVA-1207 – Phase1/2a Study Design 32 • Dose escalation in patients with mCRPC (EudraCT 2021-001789-39; NCT05369000) • Primary objectives: investigate safety and tolerability of LAVA-1207 • Secondary objectives: evaluate PK, PD, immunogenicity and preliminary signs of antitumor activity • LAVA-1207
Slide 33: LAVA-1207 Patient Baseline Characteristics
LAVA-1207 – Patient Baseline Characteristics 33 N=20 Age, median (range) 68 (51-76) Years since diagnosis, median (range) 9 (3-21) Prior systemic therapies, median (range) 4 (3-10) Location of metastases Bone 19 Lymph node 14 Lung 2 Liver 5 Other visceral 2 Type of progression PSA 17 Bone 12 Nodal 1
Slide 34: LAVA-1207 Time on Treatment
LAVA-1207 – Time on Treatment Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 34 Data cut-off date: 8 Dec 2022 • A dose level (DL) of 120 µg (starting dose, 1.5 µg, MABEL approach) completed – DL 1 included 6 pts, 3 from EU, 3 from US; DL 2 included 5 pts, 3 from EU, 2 from US • A total
Slide 35: LAVA-1207 Initial Phase Data - Safety
LAVA-1207 – Initial Phase 1 Data - Safety 35 Data cut-off date: 8 Dec 2022 • Most observed AEs not suspected to be related and no DLT • Treatment emergent AEs (TEAEs) that were suspected to be related were grade 1 or 2 • No increase in severity or frequency of TEAEs with increasing doses and no pati
Slide 36: LAVA-1207 Pharmacokinetics
LAVA-1207 – Pharmacokinetics Data cut-off date: 8 Dec 2022 • Pharmacokinetics of LAVA-1207 appears linear 36 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 4 Time since infusion start (h) LAVA-1207 (ng/L) 5000 N303 N304 N305 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 5 Time since infusion
Slide 37: LAVA-1207 Pharmacodynamics
LAVA-1207 – Pharmacodynamics Data cut-off date: 8 Dec 2022 • Pharmacodynamics reflect changes expected as per MoA • Pronounced drop in Vγ9Vδ2-T cell frequency 2 hr after dosing, suggesting Vγ9Vδ2-T cell re-distribution, with subsequent recovery • Vγ9Vδ2-T cell activation markers (CD25 and CD69) upre
Slide 38: LAVA-1207 Preliminary Signs of Antitumor Activity
LAVA-1207 – Preliminary Signs of Antitumor Activity 38 • Out of 14 iRECIST evaluable patients, 8 had iSD at week 8. 38 Data cut-off date: 8 Dec 2022 Patient N304 – 40 mg • Largest overall decrease in PSA was 61% (46% vs baseline) • Per treating physician, the patient improved clinically with improve
Slide 39: Summary of Initial Phase Data Presented
Summary of Initial Phase 1 Data Presented • LAVA-1207 is a PSMA targeting bispecific antibody belonging to a novel class of γδ T cell engagers (Gammabody™) • LAVA-1207 has reached a dose of 120 mg (starting dose 1.5 mg) without the occurrence of high-grade (>2) CRS or DLTs in therapy refractory mCRP
Slide 40: LAVA-1223 Licensed to Seagen
40 LAVA-1223 – Licensed to Seagen Gammabody™ for the treatment of EGFR-expressing solid tumors
Slide 41: LAVA-1223: EGFR-Targeting Gammabody
LAVA-1223: EGFR-Targeting Gammabody™ Format • Gammabody™ format containing a silenced Fc domain Mechanism of Action • Induces preferential lysis of EGFR-expressing tumor cells while relatively sparing EGFR-expressing normal cells Status • Exclusive worldwide license agreement with Seagen Inc. • Seag
Slide 42: LAVA-1266 CD123 Targeting Gammabody
42 CD123 Targeting Gammabody™ for the Treatment of Hematologic Malignancies LAVA-1266
Slide 43: LAVA-1266: CD123-Targeting Gammabody for Hematological Malignancies
Mechanism of Action • Induces preferential lysis of CD123-expressing tumor cells while relatively sparing CD123-expressing normal cells – CD123 is overexpressed in a wide range of hematological malignancies Status • CTA/IND enabling studies ongoing; filing anticipated in 2024 LAVA-1266: CD123-Target
Slide 44: Milestones
Milestones 44
Slide 45: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications
MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody™ Pipeline: Potential in Hematological and Solid Tumor Indications 45 Can
Slide 46: Gamma delta T cell engagers for next-generation cancer therapeutics
Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation February 2023
LAVA Therapeutics — Investor Presentation (February 2023) on 6ix